Previous 10 | Next 10 |
2023-07-20 10:43:40 ET Summary On August 2, 2023, Teva Pharmaceutical, one of the world's top generic drug manufacturers, will publish its financial report for the second quarter of 2023. The company has launched generic versions of several medicines and is conducting phase 2 tria...
2023-07-19 23:00:05 ET Summary Teva Pharmaceutical Industries Limited, valued at $9.2bn, is a leading player in the global generic drug industry, but its growth is not impressive and it is valued at a significant discount to the rest of the sector. The company's long-term debt inc...
2023-07-16 22:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-07-07 11:30:25 ET The Association for Accessible Medicines, which has some of the world's largest generic drug manufacturers as members, is suing the Minnesota Attorney General over a new price control law. The suit, filed in federal court in the state, aims to block the price-cont...
2023-07-07 07:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2023 financial results on Wednesday, August 2, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast, at 8:00 a.m. ET. ...
2023-07-05 01:37:54 ET Summary In December 2021, I shared key insights, top picks, and pans from seven great investors of our time. Their high conviction picks since that time reveal mixed results. Winners were Buffett, Dalio, Gross, Gundlach, and Rogers, while Munger and Miller h...
2023-07-03 06:49:30 ET Summary We check in on Catalyst Pharmaceuticals today as a lot has happened around the company since we last looked at it last summer. These include a major addition to the company's pipeline, challenges on the patent litigation front, and impressive organic...
Data presented at the European Academy of Neurology Congress 2023 Teva Pharmaceutical Industries Ltd. today announces further positive data from the pan-European PEARL study investigating the impact of AJOVY ® (fremanezumab) on the prevention of migraine in a real-world setti...
2023-06-21 11:02:52 ET The leading drug industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA) filed a lawsuit against the U.S. government on Wednesday, challenging the drug pricing negotiations introduced by the recently-enacted Inflation Reduction Act. The N...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...